title: [Experimental and clinical study of adoptive immunotherapy combined with preadministration of OK-432: a method to augment the therapeutic effect].
abstract: Our previous method of adoptive immunotherapy using IL2-cultured autologous lymphocytes consists of (1) in vitro sensitization by sonicated autologous tumor extract, (2) the induction and proliferation of active CTL by crude IL2, and (3) the preadministration of OK-432 for the augmentation of the therapeutic effect. Here we describe a new method to augment the therapeutic effect of OK432-combined AIT. In BALB/c mice with advanced malignant ascites (MOPC 104E), serial therapy with OK-432, cyclophosphamide and AIT significantly prolonged the survival compared with other therapeutic schedules through synergism between host's effector cells induced by immuno-chemotherapy and transferred killer cells. Many patients with advanced malignancies, for example, unresectable gastrointestinal cancer, locally advanced breast cancer or lung metastases of breast cancer, respond to such immuno-chemo-lymphocytotherapy, while previous OK432-combined AIT was effective only in malignant pleural effusion or metastatic liver tumor from breast cancer or peritoneal dissemination of gastric cancer.
authors: 1st Dept. of Surgery, Faculty of Medicine, Kyoto University.
authors: N
authors: N
authors: Kan
authors: T
authors: T
authors: Okino
authors: M
authors: M
authors: Nakanishi
authors: K
authors: K
authors: Sato
authors: K
authors: K
authors: Mise
authors: Y
authors: Y
authors: Teramura
authors: S
authors: S
authors: Yamasaki
authors: T
authors: T
authors: Hori
authors: K
authors: K
authors: Ohgaki
authors: T
authors: T
authors: Tobe
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000628:therapy*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D007116:Immunization, Passive / Q000379:methods; D007376:Interleukin-2 / Q000494:pharmacology; D007694:Killer Cells, Natural / Q000637:transplantation*; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000628:therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010844:Picibanil / Q000008:administration & dosage / Q000627:therapeutic use*; D014182:Transplantation, Autologous
chemical_list: D001688:Biological Products; D007376:Interleukin-2; D009944:Organoplatinum Compounds; C055423:didimethylsulfoxide dichloroplatinum(II); D010844:Picibanil; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil